Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.53 |
| ▸ | MTR | Q99707 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128653 | 0.83 | CRBN (0.62) | CRBNMTRKMT2ASCN1ASCN5A | |
| SCHEMBL21899486 | 0.81 | CRBN (0.41) | CRBNKMT2AHTR2A | |
| SCHEMBL27370438 | 0.78 | CRBN (0.38) | CRBN | |
| SCHEMBL23314138 | 0.76 | HTR2C (0.36) | CRBNHTR2CHTR2BHTR2AKDM5A | |
| SCHEMBL23915744 | 0.76 | CRBN (0.43) | CRBN | |
| SCHEMBL31252782 | 0.75 | CRBN (0.55) | CRBNMTRDPP4KMT2ASCN1A | |
| SCHEMBL29961279 | 0.74 | MTR (0.59) | CRBNMTRKMT2ASCN1ASCN5A | |
| SCHEMBL18216849 | 0.74 | MTR (0.59) | CRBNMTRKMT2ASCN1ASCN5A | |
| SCHEMBL24717673 | 0.74 | CRBN (0.50) | CRBNMTRDPP4KMT2ASCN1A | |
| SCHEMBL20331091 | 0.73 | CRBN (0.33) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CRBN 171/4885MTR 1195/4885DPP4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.